Abstract # 969 Long-Term Follow Up of Patients with Chronic HCV and No or Minimal Fibrosis Shows Low Risk for Liver-Related Morbidity and Mortality After Achieving SVR with DAA-Based Therapy: Results from the Gilead SVR Registry—M. Bourlière, et al.
The study included an analysis of 1,444 patients with minimal or no fibrosis (F0-F1) before treatment. Genotype 1 was the most common (58%), followed by genotype 2 (15%), genotype 3 (18%), and genotypes 4, 5 and 6 (9%). All of the patients received a sofosbuvir-based direct-acting antiviral therapy. The patients were followed for 144 weeks after treatment ended. The degree of liver disease progression was measured.
Conclusion: There were 6 deaths in the group of 1,444 patients but the deaths were not related to liver disease. There was only 1 patient who relapsed after treatment ended and there were 7 reinfections.
Editorial Comments: This study should reassure people with minimal or no scarring (fibrosis) that curing hepatitis C results in no further HCV liver disease progression. However, it’s important to have cholesterol levels checked after being cured since the hepatitis C virus interferes with cholesterol production.
As I mentioned in the introduction, this conference was also a watershed moment in the history of hepatitis C. There were presentations on two HCV drugs in development. Both of the drugs in development were discontinued either because they lacked effectiveness or due to market competition. These two drugs were the last drugs in development. This is good news because we now have drugs that can cure almost everyone with hepatitis C. It is the end of an era!
As a reminder, because of the discontinuation of the drugs in development,
we have discontinued our HCV Drug Pipeline.